大象传媒

The first drugs to slow Alzheimer's progression have been making headlines around the world. For researchers in the field, the arrival of these two therapies called Lecanemab and Donanemab is testament to decades of advancements in the field of Alzheimer's research because for the first time they go further than modifying the symptoms and have been shown in trials to slow down cognitive decline. For patients and families these treatments offer hope that the amount of quality time they'll have together could be lengthened.

Around the world regulatory bodies are weighing up their effectiveness, safety and cost. In the UK by the Medicines and Healthcare products Regulatory Agency (MHRA)
has approved Lecanemab and Donanemab for use but the National Institute for Health and Care Excellence (NICE) rejected them for use in the NHS on the basis the benefit to patients did not outweight the cost, although they could still be available privately.

Presenter James Gallagher examines the decision with Professor of Public Health Carol Brayne from the University of Cambridge and neuroscientist Professor Tara Spires-Jones from the University of Edinburgh. Then, looking forward, he meets scientists searching for future treatments including Dr Emma Mead, chief scientist at the Alzheimer's UK Drug Discovery Institute at the University of Oxford, Dr Ashvini Keshavan, co-lead of University College London's ADAPT blood biomarker trial, Selina Wray, Professor of Molecular Neuroscience and Alzheimer's Research UK Senior Research Fellow at University College London, and UK Dementia Research Institute Emerging Leader Dr Claire Durrant.

This programme was produced in partnership with The Open University.

Presenter: James Gallagher
Producer: Tom Bonnett
Editor: Holly Squire